Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BCAX
BCAX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCAX News
Bicara Therapeutics Grants Stock Options to New Employee
6d ago
Newsfilter
Bicara Therapeutics Announces Public Offering Details
Feb 25 2026
seekingalpha
Bicara Therapeutics Prices Public Offering at $16.00 per Share
Feb 25 2026
Newsfilter
Bicara Therapeutics Launches $150M Public Offering
Feb 24 2026
seekingalpha
Bicara Therapeutics Presents New Data on Ficerafusp Alfa Therapy
Feb 19 2026
Newsfilter
Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa
Dec 06 2025
Globenewswire
Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study
Dec 06 2025
Newsfilter
Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose
Dec 01 2025
Newsfilter
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated
Nov 20 2025
Globenewswire
Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11
Nov 11 2025
Benzinga
Bicara Therapeutics Reports Reduced Net Loss in Q3
Nov 10 2025
Yahoo Finance
What’s Driving Bicara Therapeutics' Pre-Market Surge?
Oct 13 2025
NASDAQ.COM
Bicara Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for Ficerafusp Alfa in First-Line Treatment of HPV-Negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Oct 13 2025
Newsfilter
Bicara Therapeutics submits $400M mixed securities shelf registration
Oct 03 2025
SeekingAlpha
Analysts Predict 10% Growth Potential for SCHB Holdings
Oct 02 2025
NASDAQ.COM
Piper Sandler Begins Coverage of Bicara Therapeutics with an Overweight Rating and Sets Price Target at $36
Aug 19 2025
Benzinga
Show More News
